Press release

Industry Welcomes 3rd EC Workshop on Biosimilars

Welcoming efforts to promote the exchange of neutral information and learnings on biosimilars

  • The European Commission today organised its 3rd workshop on biosimilar medicines, bringing together patients, doctors, pharmacists, academics, authorities, and industry across Europe.
  • During the workshop, the European Commission and European Medicines Agency (EMA) also launched an information guide on biosimilars for healthcare professionals to provide EU healthcare professionals with reference information on the science and regulation underpinning the use of biosimilars medicines.
  • EFPIA, EuropaBio and Medicines for Europe, welcome both efforts to further promote the exchange of neutral information and learnings on biosimilars between stakeholders

Brussels, 5 May 2017 - The European pharmaceutical industry welcomes the 3rd workshop on access to biosimilars, organised today by the European Commission Directorate General for the Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) on access to biosimilar medicines in Europe. The event brought together patients, doctors, pharmacists, academics, authorities, press and industry to share experiences with biosimilar medicines across Europe.

The event has provided a great platform for information sharing on topics such as the importance of collaboration in encouraging the use of biosimilar medicines and building stakeholder confidence in biosimilar medicines through evidence-based information sharing.

In addition, following the successful launch of a Q&A for patients on biosimilar medicines at the end of 2016, the European Commission and EMA have jointly introduced an information guide for healthcare professionals. This document provides reliable information for EU healthcare professionals with reference information on the science and regulation underpinning the use of biological medicines, including biosimilars.

The European pharmaceutical industry fully supports the increased competition in the biologics markets and its contribution to the sustainability of healthcare systems and commends the European Commission which has contributed to the acceptance of and trust in biosimilar medicines in Europe. The broad range of stakeholders that attended the event from across Europe reflects the increasing interest and relevance of biosimilar medicines.

 

About the issuers of this press release

The industry is represented by the European Federation of Pharmaceutical Industries, and Associations (EFPIA), the European Association for Bioindustries (EuropaBio) and Medicines for Europe-Biosimilar Medicines Group.

For further information, please contact:

EFPIA: Communications Team, +32 2626 2555, communications@efpia.eu

EuropaBio: Cosmin Popa, +32 2 739 11 73, c.popa@europabio.org

Medicines for Europe: Doris Casares, +32 2 533 98 18, doris@medicinesforeurope.com